Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

PubMed Links for Books (Select 2194600)

1.

The asparaginyl endopeptidase legumain after experimental stroke.

Ishizaki T, Erickson A, Kuric E, Shamloo M, Hara-Nishimura I, Inácio AR, Wieloch T, Ruscher K.

J Cereb Blood Flow Metab. 2010 Oct;30(10):1756-66. doi: 10.1038/jcbfm.2010.39. Epub 2010 Mar 17.

2.
3.

Diverse regulatory roles for lysosomal proteases in the immune response.

Colbert JD, Matthews SP, Miller G, Watts C.

Eur J Immunol. 2009 Nov;39(11):2955-65. doi: 10.1002/eji.200939650. Review.

PMID:
19637232
4.

Delineating protease functions during cancer development.

Affara NI, Andreu P, Coussens LM.

Methods Mol Biol. 2009;539:1-32. doi: 10.1007/978-1-60327-003-8_1. Review.

PMID:
19377975
5.

Use of fluorescent imaging to investigate pathological protease activity.

Blum G.

Curr Opin Drug Discov Devel. 2008 Sep;11(5):708-16. Review.

PMID:
18729022
6.

Applications for chemical probes of proteolytic activity.

Bogyo M, Baruch A, Jeffery DA, Greenbaum D, Borodovsky A, Ovaa H, Kessler B.

Curr Protoc Protein Sci. 2004 Sep;Chapter 21:Unit 21.17. doi: 10.1002/0471140864.ps2117s36.

PMID:
18429259
7.

Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes.

Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M.

Nat Chem Biol. 2007 Oct;3(10):668-77. Epub 2007 Sep 9.

PMID:
17828252
8.
9.

Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumain.

Sexton KB, Witte MD, Blum G, Bogyo M.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):649-53. Epub 2006 Nov 6.

10.

Mechanism-based probe for the analysis of cathepsin cysteine proteases in living cells.

Hang HC, Loureiro J, Spooner E, van der Velden AW, Kim YM, Pollington AM, Maehr R, Starnbach MN, Ploegh HL.

ACS Chem Biol. 2006 Dec 20;1(11):713-23.

PMID:
17184136
11.

Specificity of aza-peptide electrophile activity-based probes of caspases.

Sexton KB, Kato D, Berger AB, Fonovic M, Verhelst SH, Bogyo M.

Cell Death Differ. 2007 Apr;14(4):727-32. Epub 2006 Dec 15.

12.

Legumain expression as a prognostic factor in breast cancer patients.

Gawenda J, Traub F, Lück HJ, Kreipe H, von Wasielewski R.

Breast Cancer Res Treat. 2007 Mar;102(1):1-6. Epub 2006 Sep 21.

PMID:
17028987
13.

Targeting tumor-associated macrophages as a novel strategy against breast cancer.

Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, Xiang R.

J Clin Invest. 2006 Aug;116(8):2132-2141.

14.

Activity-based probes that target diverse cysteine protease families.

Kato D, Boatright KM, Berger AB, Nazif T, Blum G, Ryan C, Chehade KA, Salvesen GS, Bogyo M.

Nat Chem Biol. 2005 Jun;1(1):33-8. Epub 2005 May 24.

PMID:
16407991
15.

A general solid phase method for the preparation of diverse azapeptide probes directed against cysteine proteases.

Kato D, Verhelst SH, Sexton KB, Bogyo M.

Org Lett. 2005 Dec 8;7(25):5649-52.

PMID:
16321013
16.

Cysteine proteases as disease markers.

Berdowska I.

Clin Chim Acta. 2004 Apr;342(1-2):41-69. Review.

PMID:
15026265
17.

Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases).

James KE, Götz MG, Caffrey CR, Hansell E, Carter W, Barrett AJ, McKerrow JH, Powers JC.

Biol Chem. 2003 Dec;384(12):1613-8.

PMID:
14719804
18.

Sequential autolytic processing activates the zymogen of Arg-gingipain.

Mikolajczyk J, Boatright KM, Stennicke HR, Nazif T, Potempa J, Bogyo M, Salvesen GS.

J Biol Chem. 2003 Mar 21;278(12):10458-64. Epub 2003 Jan 17.

19.

Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases.

Asgian JL, James KE, Li ZZ, Carter W, Barrett AJ, Mikolajczyk J, Salvesen GS, Powers JC.

J Med Chem. 2002 Nov 7;45(23):4958-60.

PMID:
12408706
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk